Kantor, Olga
Burstein, Harold J.
King, Tari A.
Shak, Steven
Russell, Christy A.
Giuliano, Armando E.
Hortobagyi, Gabriel N.
Winer, Eric P.
Korde, Larissa A.
Sparano, Joseph A.
Mittendorf, Elizabeth A. http://orcid.org/0000-0002-9762-8536
Article History
First Online: 28 July 2022
Disclosure
: E.A.M. reports compensated service on scientific advisory boards for AstraZeneca, Exact Sciences, Merck, and Roche/Genentech; uncompensated service on steering committees for Bristol Myers Squibb, Lilly, and Roche/Genentech; and institutional research support from Roche/Genentech (via SU2C grant) and Gilead. E.A.M. reports the following nonfinancial interests, nonremunerated activities: Board of Directors for the American Society of Clinical Oncology and Scientific Advisor for Susan G. Komen for the Cure Foundation. T.A.K. reports Speakers Honoraria and compensated service on scientific Advisory Board of Exact Sciences (formerly Genomic Health, Inc.) and compensated service for a Global Advisory Board of Besins Healthcare. C.A.R. and S.S. report employment by Exact Sciences (formerly Genomic Health, Inc.) and stock ownership of Exact Sciences. E.P.W. reports institutional research funding from Genentech/Roche; serving as a consultant for Athenex, Carrick Therapeutics, G1 Therapeutics, Genentech/Roche, Genomic Health, Gilead, GlaxoSmithKline, GSK, Jounce, Lilly, St. Lucia, Syros, and Zymeworks; a non-paid scientific advisory board membership at Leap Therapeutics; and serving as President-Elect of ASCO. All remaining authors have declared no conflicts of interest.
: Data were obtained with permission though the National Clinical Trials Network (NCTN) data archive. Secondary data use was approved by the Brigham and Women’s Institutional Review Board. Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) guidelines were followed.